AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Exclusion Criteria

• •Active CNS lymphoma or CNS involvement unless there is a history of at least 3 months of sustained remission of treated disease.
• •History of clinically significant structural cardiac disease.
• •Cardiac ejection fraction of \< 45% on echocardiogram or MUGA scan at screening assessment.
• •Inadequate pulmonary function.
• •History of a solid organ allograft, or an inflammatory or autoimmune disease likely to be exacerbated by IL-2.
• •Ongoing uncontrolled systemic infections.
• •Positive HIV PCR test
• •Positive for Hepatitis B or Hepatitis C
• •Prior allogeneic stem cell transplant.
• •Females of childbearing potential must be willing and able to use appropriate contraception for duration of trial and for 6 months following final AB-101 dose. Males must be sterile or commit to using appropriate contraception until 90 days following the final dose of AB-101.
• •Individuals who are pregnant or lactating are ineligible.
• •Patients who received a previous genetically modified cell therapy product (e.g., CD19 CAR-T), and progressed within 120 days from the time of the cell therapy infusion